3D Human CNS Brain Organoid Supply and Culture Services

The contract outlines the provision of human induced pluripotent stem cell-derived three-dimensional brain organoids at a 10-week differentiation stage, to be delivered with ongoing culture maintenance and rigorous quality control measures to ensure suitability for electrophysiological and transcriptomic analyses. The organoids must be produced under standardized conditions that preserve structural integrity, cellular composition, and functional maturation necessary for high-resolution neurobiological research. The supplier is responsible for sustaining optimal growth environments throughout the differentiation timeline and implementing validated assays to confirm developmental milestones, purity, and consistency across batches. This subcontract, issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, is classified under NAICS code 325411 for pharmaceutical and biological product manufacturing and is intended to support advanced neurological research initiatives. Responses are due by July 6, 2026, with no set-aside provisions designated, indicating open competition. The work will be conducted in alignment with regulatory and scientific standards required for generating reproducible, high-fidelity human neural models, though the specific performance location and point of contact details are not provided in the available data.